Targeting c-KIT, PDGFR in cancer of unknown primary: A screening study for molecular markers of benefit

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 6, 2008, Pages 697-704

  Dova, L ^a   Pentheroudakis, G ^a   Golfinopoulos, V ^a   Malamou Mitsi, V ^a   Georgiou, I ^a   Vartholomatos, G ^a   Ntemou, A ^b   Fountzilas, G ^c   Pavlidis, N ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b G Chatzikosta General State Hospital   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

C KIT; Cancer of unknown primary; Immunohistochemistry; Mutations; PDGFR

Indexed keywords

BIOTIN; MOLECULAR MARKER; PEROXIDASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; STREPTAVIDIN;

ADULT; AGED; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER SCREENING; CLINICAL ARTICLE; CORRELATION ANALYSIS; EXON; FEMALE; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MALE; OUTCOME ASSESSMENT; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

AGED; AGED, 80 AND OVER; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, UNKNOWN PRIMARY; PIPERAZINES; POLYMORPHISM, GENETIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 41849130666     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0341-7     Document Type: Article

References (39)

1. Buchdunger E, Cioffi CL, Law N et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139-145
2. Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K (2003) Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 39(6):793-799
3. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F (2005) Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 7(5):R788-R795
4. Claesson-Welsh L, Eriksson A, Westermark B, Heldin CH (1989) cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor. Proc Natl Acad Sci USA 86(13):4917-4921
5. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22(18):3813-3825
6. Corless CL, Schroeder A, Griffith D et al (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23(23):5357-5364
7. Debiec-Rychter M, Dumez H, Judson I et al (2004) EORTC Soft Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40(5):689-695
8. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472-480
9. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329-1338
10. de Silva CM, Reid R (2003) Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 9(1):13-19
11. Dova L, Pentheroudakis G, Georgiou I et al (2007) Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastases 24(2):79-86
12. Gomes AL, Bardales RH, Milanezi F, Reis RM, Schmitt F (2007) Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol 127(1):1-8
13. Heinrich MC, Corless CL, Duensing A et al (2003a) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607):708-710
14. Heinrich MC, Corless CL, Demetri GD et al (2003b) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342-4349
15. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283-1316
16. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577-580
17. Hirota S, Ohashi A, Nishida T et al (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125(3):660-667
18. Johnson BE, Fischer T, Fischer B et al (2003) Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9(16 Pt 1):5880-5887
19. Kazlauskas A, Cooper JA (1989) Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. Cell 58(6):1121-1133
20. Kitamura Y, Hirotab S (2004) Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61(23):2924-2931
21. Langerak AW, De Laat PA, Van Der Linden-Van Beurden CA et al (1996) Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 178(2):151-160
22. Liegl B, Leithner A, Bauernhofer T et al (2006) Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours? Histopathology 49(6):576-581
23. Marx J. (2005) Cancer. Encouraging results for second-generation antiangiogenesis drugs. Science 308(5726):1248-1249
24. Motzer RJ, Rini BI, Bukowski RM et al (2006a) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516-2524
25. Motzer RJ, Michaelson MD, Redman BG et al (2006a) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16-24
26. Ongkeko WM, Altuna X, Weisman RA, Wang-Rodriguez J (2005) Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 124(1):71-76
27. Pentheroudakis G, Pavlidis N (2006) Perspectives for targeted therapy in cancer of unknown primary site. Cancer Treat Rev 32:637-644
28. Pentheroudakis G, Briasoulis E, Pavlidis N (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12(4):418-425
29. Peterson MR, Piao Z, Weidner N, Yi ES (2006) Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors: immunohistochemical and mutational analyses. Appl Immunohistochem Mol Morphol 14(4):390-6
30. Rashid A, Hess KR, Lenzi R, et al (2005) Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP). Journal of Clinical Oncology 2005, ASCO Annual Meeting Proceedings, Vol 23, No 16S, Part 1, June 1 Supplement, Abstract number 9683
31. Rubin BP, Singer S, Tsao C et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61(22):8118-8121
32. Shih AH, Holland EC (2006) Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 232(2):139-147
33. Sihto H, Sarlomo-Rikala M, Tynninen O et al (2005) KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 23(1):49-57
34. Sulzbacher I, Birner P, Träxler M, Marberger M, Haitel A (2003a) Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120(1):107-112
35. Sulzbacher I, Birner P, Trieb K, Träxler M, Lang S, Chott A (2003b) Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 16(1):66-71
36. Ugurel S, Hildenbrand R, Zimpfer A et al (2005) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92(8):1398-1405
37. Went PT, Dirnhofer S, Bundi M et al (2004) Prevalence of KIT expression in human tumors. J Clin Oncol 22(22):4514-4522
38. Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS (2005) Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol 36(3):242-249
39. Yarden Y, Kuang WJ, Yang-Feng T et al (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6(11):3341-3351